Azitra Begins Phase 1b Clinical Trial Dosing Of ATR-12 For Netherton Syndrome; Study To Enroll 12 Adults Over 14 Days With Interim Safety Data Expected In Early 2025 And Full Results In Second Half Of 2025
Author: Benzinga Newsdesk | August 28, 2024 08:31am